Navigation Links
FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
Date:9/23/2008

annot efficiently pump blood to meet the body's oxygen demands. The American Heart Association estimates that about six million Americans are living with heart failure, with 550,000 new cases diagnosed annually. Heart failure accounts directly for 55,000 deaths and indirectly for an additional 230,000 deaths in the United States each year. Heart failure is the underlying reason for approximately 12 to 15 million annual visits to physicians and 6.5 million annual hospital days.

About ARCA biopharma

ARCA biopharma, Inc. is a privately held company focused on developing and commercializing genetically targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product, Gencaro(TM) (bucindolol hydrochloride)*, is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for heart failure and other indications. ARCA biopharma, in partnership with Laboratory Corporation of America (NYSE: LH), is developing a companion genetic test for bucindolol. For more information please visit http://www.arcabiopharma.com.

* The tradename Gencaro(TM) is currently pending regulatory including FDA approval.


'/>"/>
SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
2. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
3. FDA Accepts Ranexa(R) sNDA and NDA for Filing
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
6. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
7. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
8. FDA Accepts Immucors Response to Warning Letter
9. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
10. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
11. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... ­ RedBrick Health , a fast-growing leader in ... that EmblemHealth , the New York ... providing the RedBrick Compass health assessment, combined with the ... its members. EmblemHealth is among the first health plans ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... 2014 As pet owners drew up their lists of New ... "Take better care of my furry companion." Nowadays there are pet ... carrying cases to take the little canine or feline darlings along ... to buy some pricey toys at the pet store. But anyone ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2
... it expands ... line of predictive diagnostic tests, EMERYVILLE, Calif., Sept. ... acquired Lipomics Technologies of West,Sacramento, Calif. The acquisition will ... terms were not disclosed., The acquisition brings together ...
... 17 Amicus Therapeutics,(Nasdaq: FOLD ), today announced ... make a presentation at the UBS Global Life Sciences,Conference ... in New York., An audio webcast of the ... http://www.amicustherapeutics.com . Participants should allow,approximately five to ten ...
... a finding that could speed the use of sensors or ... shown that certain types of tiny organic particles, when heated ... layer of a thin polymer film and then can reversibly ... , Selectively bringing a number of particles to a surface ...
Cached Biology Technology:Tethys Bioscience Announces Acquisition of Lipomics Technologies 2Tethys Bioscience Announces Acquisition of Lipomics Technologies 3NC State engineers discover nanoparticles can break on through 2
(Date:4/23/2014)... Angeles, London (April 23, 2014). "I think one can argue ... pathwayas well as doing everything else that we canthen we ... Tom Wigley, one of the world,s foremost climate researchers, in ... , published by SAGE. Refusing to take significant action on ... eventually be needed to address the problem, Wigley explains in ...
(Date:4/22/2014)... team of Yale researchers will lead a five-year, $3 ... rain events is affecting the transport of dissolved organic ... they say could alter the chemical composition and water ... With funding from the National Science Foundation,s MacroSystems Biology ... across the watershed, which begins in Canada and runs ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
Breaking Biology News(10 mins):Is nuclear power the only way to avoid geoengineering? 2Connecticut River watershed study will assess impacts of extreme rain events 2Connecticut River watershed study will assess impacts of extreme rain events 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3
... uterine fibroids and significantly relieves fibroid-related symptoms in ... clinical trial reported in the June issue of ... (MRgFUS) allows radiologists to precisely target fibroids without ... immediately stops blood flow in the treated fibroid ...
... University of Toronto researchers have uncovered the basis by ... also discovered how the HIV virus works to counteract ... for pregnant women in malaria-ravished regions. , Malaria is ... than one million people every year. While the disease ...
... of smell, which in many species is critical for finding ... biologists, sharks can not use just their noses to locate ... called the lateral line. The lateral line is an organ ... and vibration in the surrounding water. According to the research ...
Cached Biology News:Focused ultrasound relieves fibroid symptoms in women 2HIV and malaria combine to adversely affect pregnant women and their infants 2New research shows sharks use their noses and bodies to locate smells 2New research shows sharks use their noses and bodies to locate smells 3
...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
... Second Mitochondria Derived Activator of ... 20 mM HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. ... Smac/DIABLO with a carboxy terminal His•Tag ® ... E. coli . Smac/DIABLO is released along with ...
... to Decorin ( Abpromise for ... Antigen: Synthetic peptide: IGPEVPDDRDFEPS conjugated ... 6-19 of Human Decorin (fragment 36-49 ... II). Entrez GeneID: ...
Biology Products: